Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Exclusion Criteria

• •Patients with clinically significant cardiovascular disease as outlined in the protocol
• •Neutrophil count \< 1,500/mm3; platelet count \<100,000/m3
• •Alkaline phosphatase or bilirubin \> 1.5 x ULN, SGOT \> 5 x ULN
• •Calculated creatinine clearance \< 50ml/min
• •Prior chemotherapy or radiotherapy for other malignancy except for the treatment for localized breast cancer greater than five years prior to diagnosis
• •No more than one cycle of first line chemotherapy with carboplatin and paclitaxel
• •Inadequate surgical cytoreduction such that interval cytoreductive surgery could materially improve prognosis
• •Concurrent invasive malignancy
• •Evidence of bleeding diathesis or coagulopathy
• •Evidence of tumor involving major blood vessels on any prior CT scans
• •Surgical wound that has failed to close
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of this study
• •Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0
• •Serious non-healing wound, ulcer, or bone fracture
• •Prior treatment with an anti-angiogenic agent
• •Any active bleeding
• •Active psychiatric disease or neurologic symptoms requiring treatment
• •Presence of central nervous system brain metastases
• •Proteinuria at screening as demonstrated by criteria in protocol
• •Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent
• •Known hypersensitivity to Cremophor EL or any component of Avastin
• •Active bacterial, viral, or fungal infections
• •Receiving any other investigational agent
• •History of gastrointestinal perforation
• •Prior therapies targeting the epidermal growth factor receptor
• •Symptoms of bowel obstruction
• •Dependence on TPN or IV hydration